MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Putaminal Diffusion Imaging for the Differential Diagnosis of the Parkinsonian Variant of Multiple System Atrophy from Parkinson’s Disease: Impact of Segmentation Accuracy

    R. De Marzi, S. Bajaj, F. Krismer, B. Larcher, S. Ringler, G. Wenning, M. Schocke, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective:  To evaluate different approaches of segmentation of the putamen in order to discriminate PD from MSA-P based on putaminal diffusion imaging. Background: Differences in prognosis…
  • 2017 International Congress

    The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

    R. Borgemeester, T. van Laar (Groningen, Netherlands)

    Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…
  • 2017 International Congress

    Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease

    J. Etcheverry, M. Cesarini, G. Rojas, E. Gatto (Buenos Aires, Argentina)

    Objective: to determine whether Dextrometorphan/quinidine (DMQ) is effective in the treatment of PBA, AG or bulbar symptoms in corticobasal syndrome (CBS), multiple system atrophy (MSA),…
  • 2017 International Congress

    Validation of a performance-based assessment of functional ability related to cognition in Parkinson’s disease

    S. Holden, L. Medina, B. Hoyt, S. Sillau, J. Goldman, D. Weintraub, B. Kluger (Aurora, CO, USA)

    Objective: Validate the University of California San Diego Performance-Based Skills Assessment (UPSA) in Parkinson's disease (PD) Background: Diagnostic criteria for PD dementia (PDD) require significant…
  • 2017 International Congress

    Cognitive strategy use during daily activities in people with Parkinson’s Disease

    I. Sturkenboom, E. Steultjens, M. Nott, C. Chapparo (Nijmegen, Netherlands)

    Objective: To identify difficulties in cognitive strategy use observed in people with Parkinsons’s disease (PD) during performance of everyday activities. Background: People use cognitive strategies…
  • 2017 International Congress

    The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients

    I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, K. Brockmann, T. Gasser, S. Becker, J. Streffer, D. Berg (Tübingen, Germany)

    Objective: To define cerebrospinal fluid (CSF) levels of Amyloid-beta 1-42 (Aß1-42-), total (h-) and phosphorylated (p-)Tau in a large cohort of non-demented Parkinson’s disease (PD)…
  • 2017 International Congress

    Pro-saccades predict decline in attention over 18months in newly diagnosed Parkinson’s disease

    S. Stuart, L. Alcock, J. Nell, R. Lawson, R. Morris, A. Yarnall, D. Burn, L. Rochester (Newcastle Upon Tyne, United Kingdom)

    Objective: This study investigated 1) pro-saccades in a newly diagnosed cohort of Parkinson’s disease (PD) compared to healthy older adult controls at baseline, and 2)…
  • 2017 International Congress

    Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

    G. Pagano, T. Yousaf,, C. Loane, S. Polychronis, H. Wilson, B. Giordano, F. Niccolini, M. Politis (London, United Kingdom)

    Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…
  • 2017 International Congress

    Patient-derived GBA1-PARK2 double-mutant cellular models to study the effect of GBA1 as a modifier of familial Parkinson’s disease

    Z. Hanss, I. Boussaad, P. Barbuti, S. Goldwurm, R. Krüger (Belvaux, Luxembourg)

    Objective: In this study, we propose to decipher the role of GBA1 as a modifier of familial Parkinson’s disease (PD) using double-mutant patient-derived cellular models…
  • 2017 International Congress

    Neuroprotection of indole-derivative compound NC001-8 in Parkinson disease cell model by regulatory of NRF2 pathway

    P.-C. Wei (Tao-Yuan, Taiwan)

    Objective: The goal of this study is to investigate the effects of indole-derivative compound NC001-8 on neuroprotection in PD disease cell model. Background: Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley